GlassScriptPhysician profile
Michael Lane Anthony
NPI 1891769154
$2,974.73
in general payments reported to CMS, 2019-2025
37 companies · $50.91 in 2025
The $50.91 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $364 · 2021: $621 · 2022: $457 · 2023: $822 · 2024: $293 · 2025: $50.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,165.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $427.38 | 2023 | Myrisk |
| Mayne Pharma Commercial LLC | $396.48 | 2019-2023 | |
| Hologic Sales and Service, LLC | $287.71 | 2022-2024 | Acessa Provu System, Coolseal Generator, Myosure Tissue Removal Device |
| Abbvie INC. | $281.29 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Pfizer INC. | $237.50 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $140.09 | 2019-2024 | |
| Coopersurgical, INC. | $132.53 | 2019-2025 | Endosee |
| Therapeuticsmd, INC. | $124.80 | 2019-2021 | |
| Avion Pharmaceuticals | $110.11 | 2019-2023 | Balcoltra |
| Exeltis, USA INC. | $96.60 | 2019-2023 | Slynd |
| Myovant Sciences INC. | $75.83 | 2021-2022 | |
| Shield Therapeutics INC | $66.19 | 2022-2024 | Accrufer |
| Aspira Women'S Health INC | $51.31 | 2024 | Ova1 |
| Evofem Biosciences, INC. | $46.65 | 2021-2024 | |
| Astellas Pharma US INC | $42.99 | 2024 | Veozah |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $41.57 | 2021-2023 | |
| Daiichi Sankyo INC. | $40.32 | 2020-2021 | |
| Duchesnay USA Incorporated | $36.80 | 2019 | |
| Organon LLC | $31.04 | 2022 | |
| Ethicon US, LLC | $30.70 | 2019 | |
| Novo Nordisk INC | $29.54 | 2025 | Wegovy |
| Ascend Therapeutics US, LLC | $23.65 | 2022 | |
| Abbott Laboratories | $22.35 | 2021 | |
| Agile Therapeutics, INC. | $20.72 | 2023 | Twirla |
| Mission Pharmacal Company | $19.01 | 2020 | |
| Millicent US INC | $18.73 | 2024 | Intrarosa, Femring |
| Medicem INC. | $18.04 | 2020 | |
| Lupin INC. | $16.06 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $15.42 | 2024 | |
| Terumo Medical Corporation | $14.90 | 2020 | |
| Roche Diagnostics Corporation | $14.25 | 2019 | |
| Allergan, INC. | $13.67 | 2019 | |
| Amgen INC. | $13.63 | 2020 | |
| Amag Pharmaceuticals, INC. | $13.23 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.59 | 2019 | |
| Covidien LP | $11.05 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Anthony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.